In:
American Journal of Nephrology, S. Karger AG, Vol. 30, No. 3 ( 2009), p. 244-252
Abstract:
〈 i 〉 Aims: 〈 /i 〉 Our aim was to evaluate the prognostic value of 2 measurements of serum adiponectin levels for all-cause mortality and cardiovascular (CV) mortality in uremic patients. 〈 i 〉 Methods: 〈 /i 〉 We analyzed 184 patients (19–86 years) undergoing peritoneal dialysis (n = 86) or hemodialysis (n = 98). All patients had 2 measurements of serum adiponectin levels (at baseline and after 1 year). Relationships between adiponectin and mortality were studied by means of survival analysis and Cox regression analysis. 〈 i 〉 Results: 〈 /i 〉 During a median follow-up time of 31.2 months, 67 patients (36.4%) died, 26 (14.1%) as a result of CV disease. Mean survival time for CV mortality in patients with 1-year adiponectin values in the upper tertile was significantly higher than that found in patients in the middle and lower tertiles. Hazard ratios (HR) for all-cause mortality per SD change were 0.70 (95% CI, 0.50–0.98; p 〈 0.05) for baseline adiponectin levels and 0.68 (0.49–0.95; p 〈 0.05) for mean baseline and 1-year adiponectin levels. Mean adiponectin levels were also negatively related with CV mortality [HR 0.43 (0.21–0.86); p 〈 0.05] and CV events [HR 0.74 (0.55–0.99); p 〈 0.05]. 〈 i 〉 Conclusions: 〈 /i 〉 In this population of dialysis patients, adiponectin seems to behave as a CV protective factor. Patients with high mean adiponectin levels had a better survival rate.
Type of Medium:
Online Resource
ISSN:
0250-8095
,
1421-9670
Language:
English
Publisher:
S. Karger AG
Publication Date:
2009
detail.hit.zdb_id:
1468523-1
